AI assistant
C4 Therapeutics, Inc. — Director's Dealing 2022
Feb 16, 2022
33861_dirs_2022-02-16_c7cd1c0f-8594-41b5-8cb7-7b9786b4e756.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2022-02-14
Reporting Person: Siegel Jolie (Chief Legal Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-14 | Stock Option (Right to Buy) | $22.71 | A | 90000 | Acquired | 2032-02-13 | Common Stock (90000) | Direct |
| 2022-02-14 | Performance Restricted Stock Units | $ | A | 26250 | Acquired | 2025-02-28 | Common Stock (26250) | Direct |
Footnotes
F1: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022.
F2: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones.